The estimated Net Worth of Garrison J. Hasara is at least $456 Tausend dollars as of 2 December 2019. Mr Hasara owns over 13,500 units of Inhibitor Therapeutics stock worth over $317,804 and over the last 5 years he sold INTI stock worth over $0. In addition, he makes $137,747 as CFO, Treasurer und Corp. Sec. & Chief Compliance Officer at Inhibitor Therapeutics.
Sign up
Mr CPA INTI stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Inhibitor Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 13,500 units of INTI stock worth $945 on 2 December 2019.
The largest trade he's ever made was buying 13,500 units of Inhibitor Therapeutics stock on 2 December 2019 worth over $945. On average, Mr trades about 4,500 units every 0 days since 2019. As of 2 December 2019 he still owns at least 3,972,544 units of Inhibitor Therapeutics stock.
You can see the complete history of Mr Hasara stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Garrison J. Hasara CPA, CPA biography
Garrison J. Hasara CPA, CPA is the CFO, Treasurer, Corp. Sec. & Chief Compliance Officer at Inhibitor Therapeutics.
What is the salary of Mr CPA?
As the CFO, Treasurer und Corp. Sec. & Chief Compliance Officer of Inhibitor Therapeutics, the total compensation of Mr CPA at Inhibitor Therapeutics is $137,747. There are 1 executives at Inhibitor Therapeutics getting paid more, with Nicholas Jon Virca having the highest compensation of $144,684.
How old is Mr CPA?
Mr CPA is 52, he's been the CFO, Treasurer und Corp. Sec. & Chief Compliance Officer of Inhibitor Therapeutics since . There are 1 older and no younger executives at Inhibitor Therapeutics. The oldest executive at Inhibitor Therapeutics, Inc. is Nicholas Jon Virca, 75, who is the Pres & CEO.
What's Mr CPA's mailing address?
Garrison's mailing address filed with the SEC is 449 SOUTH 12TH STREET, UNIT 1705, , TAMPA, FL, 33602.
Insiders trading at Inhibitor Therapeutics
Over the last 5 years, insiders at Inhibitor Therapeutics have traded over $0 worth of Inhibitor Therapeutics stock and bought 13,500 units worth $945 . The most active insiders traders include James A Mcnulty, W. Mark Watson und Samuel P Jr Sears. On average, Inhibitor Therapeutics executives and independent directors trade stock every 0 days with the average trade being worth of $1,080. The most recent stock trade was executed by Garrison J. Hasara on 2 December 2019, trading 13,500 units of INTI stock currently worth $945.
What does Inhibitor Therapeutics do?
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
What does Inhibitor Therapeutics's logo look like?
Complete history of Mr Hasara stock trades at Inhibitor Therapeutics
Inhibitor Therapeutics executives and stock owners
Inhibitor Therapeutics executives and other stock owners filed with the SEC include:
-
Nicholas Jon Virca,
Pres & CEO -
Garrison J. Hasara CPA, CPA,
CFO, Treasurer, Corp. Sec. & Chief Compliance Officer -
Pharma Ventures Pty Ltd May...,
-
Debra Peattie,
Director -
Robert Daniel Martin,
Director -
Garrison J. Hasara,
CFO and Treasurer -
Richard Dana Ono,
Director -
Nicholas J Virca,
President and CEO -
W. Mark Watson,
Director -
Michelle Yanez,
Director -
James A Mcnulty,
CHIEF FINANCIAL OFFICER -
Ronald E Ronald E Osman Irr...,
-
Samuel P Jr Sears,
Director -
Michael Allen Jerman,
Director